Fisher Wallace Laboratories, Inc.

Brooklyn, NYFounded 20071–10 employeesfisherwallace.comLinkedIn

Neuromodulation

Fisher Wallace Labs develops technology designed to support stress management and improved sleep. Its Fisher Wallace Stimulator is used by more than 100,000 customers and is supported by a 30-day full-refund policy and five-year warranty.

Visit fisherwallace.com ↗

Founded: 2007
Employees: 1–10

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Fisher Wallace Laboratories has continued to finance its neurostimulation business through repeated equity crowdfunding activity, including a $433,143 round announced on Sep 16, 2026 and earlier rounds of $195,452 on Dec 23, 2025 and $228,289 on Nov 6, 2025. The company’s recent intellectual-property activity centers on transcranial alternating current stimulation: a U.S. patent publication was recorded on Apr 1, 2024, followed by a related Mexican publication on Sep 29, 2025. Its product portfolio includes the Fisher Wallace Stimulator, OAK, and a patient-support service. The company states that its technology has reached more than 100,000 customers and supports the core device with a 30-day refund policy and five-year warranty. Kelly Roman remains Co-Founder and CEO, while Chip Fisher is listed as Co-Founder and Chairman. Public information does not identify material hiring activity, layoffs, new strategic partnerships, or awards through Oct 6, 2026, so the clearest recent milestones are continued fundraising, patent activity, and ongoing commercialization of wearable brain-stimulation products.

Market position

Fisher Wallace operates at the intersection of medical devices, digital health, wellness, and consumer wearables. Its differentiation is a hardware-led approach to noninvasive neurostimulation rather than a software-only mental-health platform: the Fisher Wallace Stimulator and OAK are designed for self-administered electrical brain stimulation addressing depression, anxiety, stress management, and sleep. The company describes patented waveforms intended to stimulate the brain and support mood and sleep regulation, while its website emphasizes flexible electrode receptacles, an adjustable headband system, replacement components, and direct patient support. This creates a relatively integrated product-and-service model, but also places the business in a clinically and regulatorily sensitive category where evidence, reimbursement, physician adoption, and consumer trust are important competitive factors. Available comparable-company records do not provide verified competitor names, preventing a precise peer ranking. The company appears to be a small, private specialist: its recorded employee band is one to ten people, while its products have reportedly reached more than 100,000 customers.

Growth & opportunities

Fisher Wallace’s trajectory shows a long operating history combined with an unusually sustained reliance on small equity-crowdfunding financings. Founded in 2007, the company recorded a $4.7 million crowdfunding campaign in October 2021, a $1.9 million campaign in March 2022, and a $2.5 million investment round led by SHUFL Capital on Mar 29, 2022. It then reported additional crowdfunding rounds from $181,498 to $1.16 million between May 2022 and February 2023, followed by seven more rounds from March 2024 through September 2026. The latest disclosed round, $433,143 on Sep 16, 2026, brings structured funding totals to $12,654,673 across 15 rounds. Product expansion is represented by OAK alongside the established Fisher Wallace Stimulator and patient-support service. Patent publications related to tACS in 2024 and 2025 indicate continuing technology development. The pattern therefore indicates persistent capital raising and incremental product/IP development, rather than clearly documented rapid headcount or commercialization acceleration.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Fisher Wallace Laboratories, Inc. distinct

reccy insights

What makes Fisher Wallace Laboratories, Inc. distinct

01Focuses on stress management and sleep support through scientifically validated technology.
02Fisher Wallace technology has been used by more than 100,000 customers.
03Offers a 30-day full-refund policy with return shipping included.
04Provides a five-year warranty for its stimulator device.
05Supports the core device with replacement electrodes, sponge receptacles, lead wires, and adjustable headbands.

Technology & products3

Technology & products

OAK
A wearable brain stimulation device designed to treat depression, anxiety, and other mental health conditions through self-administered electrical brain stimulation.
Fisher Wallace Stimulator
A wearable neurostimulation device cleared by the FDA to treat depression, anxiety, and insomnia by electrically stimulating the brain to regulate mood and sleep.
Patient Success Customer Service
A U.S.-based customer support service assisting patients who use Fisher Wallace devices through multiple communication channels.

Similar companies

Show all 6 companies

About Fisher Wallace Laboratories, Inc.

Products: OAK, Fisher Wallace Stimulator, Patient Success Customer Service
Leadership: Kelly Roman, Co-Founder and CEOChip Fisher, Co-Founder and Chairman
Focus areas: Digital health, medical devices, wellness, sleep health, stress management, consumer health, electrotherapy, hardware
Headquarters: Brooklyn, NY
Founded: 2007
Employees: 1–10